Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial

What this Trial Is About

Researchers are investigating whether a management strategy using coronary computed tomography angiography (CCTA) can better help patients with non-obstructive coronary artery disease reach their LDL cholesterol targets compared to traditional management without follow-up CCTA. The study aims to see if this approach reduces major cardiovascular and cerebrovascular events over a three-year period. Non-obstructive coronary artery disease patients face a high risk of adverse cardiovascular events and lack effective management strategies, prompting this randomized controlled trial. This multicenter trial randomly assigns patients with non-obstructive coronary artery disease to two groups: one receiving follow-up CCTA-based management and the other receiving routine clinical follow-up and laboratory examinations. The CCTA group undergoes follow-up CCTA scans to assess plaque progression, guiding treatment intensity. Both groups receive management and treatment recommendations based on their respective assessments. After one year, lipid levels will be re-evaluated, and after three years, major adverse cardiovascular and cerebrovascular events will be compared between groups. Participants will have routine clinical and laboratory evaluations alongside their assigned management strategy. Researchers will monitor LDL cholesterol control, adherence to lipid-lowering medications, hypertension and diabetes control, cardiovascular events, and quality of life. Follow-up includes imaging, laboratory tests, and clinical assessments over three years to assess the impact of follow-up CCTA on cardiovascular outcomes and lipid management effectiveness.

Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease